RxDoctor Payments Data

Turab Chevelwala

Family · Mesa, AZNPI 1841967668

Payments from drug & device makers

$1,936in general payments, 2019–2025

Across 90 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$228
  • Johnson & Johnson$217
  • Abbott$206
  • Novo Nordisk$103
  • Bayer$102
  • Merck$86
  • plus $994 from 26 others

What the payments were for

  • Food & beverage$1,92499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,936 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$85,403
Medicare patients
131
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$35,291
MounjaroTirzepatide29$30,699
TrulicityDulaglutide20$22,955
EliquisApixaban19$20,886
LantusInsulin Glargine,hum.Rec.Anlog20$1,780
Gabapentin76$1,379
Atorvastatin Calcium119$1,244
Oxycodone Hcl93$1,133
Levothyroxine Sodium109$1,073
Albuterol Sulfate HfaAlbuterol Sulfate30$916
Tamsulosin Hcl44$852
Pantoprazole Sodium47$815
Aripiprazole11$782
Methylphenidate Hcl12$715
Zolpidem Tartrate79$699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$228$53,65549 claims
Novo NordiskOzempic$103$35,29138 claims
PfizerEliquis$41$20,88619 claims
Sanofi-aventis U.S. LLCLantus$60$1,78020 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$70$1,073109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →